CXCR4 and plasma cell myeloma: In addition to the above described, established systemic treatments as well as novel investigational drugs that directly or indirectly target the CXCR4/CXCL12 axis 10-12,34, a theranostic approach using [177Lu]Pentixather has shown great promise in multiple myeloma and acute leukemia 35-37.